Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Esophagus Resection | Research article

RETRACTED ARTICLE: Comparison of minimally invasive Ivor Lewis esophagectomy and left transthoracic esophagectomy in esophageal squamous cell carcinoma patients: a propensity score-matched analysis

Authors: Qi Wang, Zixiang Wu, Tianwei Zhan, Shuai Fang, Sai Zhang, Gang Shen, Ming Wu

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

To investigate the long-term efficacy of the minimally invasive Ivor Lewis esophagectomy (MIILE) in esophageal squamous cell carcinoma (ESCC) patients, a retrospective comparison of the quality of life (QOL) and survival between patients who underwent MIILE and left transthoracic esophagectomy (Sweet approach) was conducted.

Methods

A detailed database search identified 614 patients who underwent MIILE and 243 patients who underwent Sweet esophagectomy between January 2011 and December 2017. After propensity score matching, 216 paired cases were selected for statistical analysis. Survival was evaluated with Kaplan-Meier curves or Cox models.

Results

MIILE was associated with a longer duration, less blood loss and more lymph node dissected than Sweet esophagectomy. MIILE patients suffered from less pain, less frequently developed pneumonia, and had fewer postoperative complications. Additionally, MIILE patients began oral intake earlier and had a shorter postoperative hospital stay, and enhanced recovery of QOL. There was no significant difference between the approaches regarding the recurrence pattern, 2-year and 5-year overall survival (OS) or disease-free survival (DFS), except that patients with tumor-node-metastasis (TNM) stage I in the MIILE group demonstrated superior OS and DFS. Pathological TNM stage and postoperative complications were determined to be independent prognostic factors based on the multivariate analysis.

Conclusion

MIILE is a safe and feasible approach for treating ESCC patients. MIILE approach may provide more postoperative advantages, enhanced QOL improvement, and more favorable long-term survival in early stage patients than the Sweet procedure.
Literature
1.
Mao YS, He J, Xue Q, Shao K, Su K, Li N, et al. Nationwide speaking tour of standardized diagnosis and treatment for esophageal cancer. Zhonghua Wei Chang Wai Ke Za Zhi. 2013;16(9):801–4.PubMed
2.
Takeuchi H, Miyata H, Ozawa S, Udagawa H, Osugi H, Matsubara H, et al. Comparison of short-term outcomes between open and minimally invasive Esophagectomy for esophageal Cancer using a Nationwide database in Japan. Ann Surg Oncol. 2017;24(7):1821–7.CrossRefPubMed
3.
Sihag S, Kosinski AS, Gaissert HA, Wright CD, Schipper PH. Minimally invasive versus open Esophagectomy for esophageal Cancer: a comparison of early surgical outcomes from the Society of Thoracic Surgeons National Database. Ann Thorac Surg. 2016;101(4):1281–9.CrossRefPubMed
4.
Holscher AH, Bollschweiler E, Schneider PM, Siewert JR. Prognosis of early esophageal cancer. Comparison between adeno- and squamous cell carcinoma. Cancer. 1995;76(2):178–86.CrossRefPubMed
5.
Eroglu A, Aydin Y, Yilmaz O, Ulas AB. An outcome comparison of adenocarcinoma of the esophagus to squamous cell carcinoma after transthoracic esophagectomy. Turkish Journal of Thoracic and Cardiovascular Surgery. 2013;21(2):402–7.CrossRef
6.
7.
Pennathur A, Awais O, Luketich JD. Technique of minimally invasive Ivor Lewis Esophagectomy. Ann Thorac Surg. 2010;89(6):S2159–62.CrossRefPubMed
8.
9.
Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC Cancer staging manual: esophagus and Esophagogastric junction. Ann Surg Oncol. 2010;17(7):1721–4.CrossRefPubMed
10.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European-organization-for-research-and-treatment-of-Cancer Qlq-C30 - a quality-of-life instrument for use in international clinical-trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.CrossRefPubMed
11.
Blazeby JM, Conroy T, Hammerlid E, Fayers P, Sezer O, Koller M, et al. Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer. Eur J Cancer. 2003;39(10):1384–94.CrossRefPubMed
12.
Ma J, Zhan C, Wang L, Jiang W, Zhang YX, Shi Y, et al. The Sweet approach is still worthwhile in modern Esophagectomy. Ann Thorac Surg. 2014;97(5):1728–33.CrossRefPubMed
13.
Li B, Hu H, Zhang YW, Zhang J, Miao LS, Ma LF, et al. Extended right thoracic approach compared with limited left thoracic approach for patients with middle and lower esophageal squamous cell carcinoma three-year survival of a prospective, randomized, open-label trial. Ann Surg. 2018;267(5):826–32.CrossRefPubMed
14.
Tapias LF, Mathisen DJ, Wright CD, Wain JC, Gaissert HA, Muniappan A, et al. Outcomes with open and minimally invasive Ivor Lewis Esophagectomy after neoadjuvant therapy. Ann Thorac Surg. 2016;101(3):1097–103.CrossRefPubMed
15.
Li B, Xiang JQ, Zhang YW, Li HC, Zhang J, Sun YH, et al. Comparison of Ivor-Lewis vs Sweet Esophagectomy for esophageal squamous cell carcinoma a randomized clinical trial. Jama Surg. 2015;150(4):292–8.CrossRefPubMed
16.
Wang H, Shen YX, Feng MX, Zhang Y, Jiang W, Xu ST, et al. Outcomes, quality of life, and survival after esophagectomy for squamous cell carcinoma: a propensity score-matched comparison of operative approaches. J Thorac Cardiovasc Surg. 2015;149(4):1006–14.CrossRefPubMed
17.
Biere SSAY, Henegouwen MIV, Maas KW, Bonavina L, Rosman C, Garcia JR, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet. 2012;379(9829):1887–92.CrossRefPubMed
18.
Sihag S, Wright CD, Wain JC, Gaissert HA, Lanuti M, Allan JS, et al. Comparison of perioperative outcomes following open versus minimally invasive Ivor Lewis oesophagectomy at a single, high-volume Centre. Eur J Cardiothorac Surg. 2012;42(3):430–7.CrossRefPubMed
19.
Hamai Y, Hihara J, Emi M, Furukawa T, Ibuki Y, Yamakita I, et al. Treatment outcomes and prognostic factors after recurrence of esophageal squamous cell carcinoma. World J Surg. 2018;42(7):2190–8.CrossRefPubMed
20.
Chen JQ, Pan JJ, Liu J, Li JC, Zhu KS, Zheng XW, et al. Postoperative radiation therapy with or without concurrent chemotherapy for node-positive thoracic esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2013;86(4):671–7.CrossRefPubMed
21.
Heroor A, Fujita H, Sueyoshi S, Tanaka T, Toh U, Mine T, et al. Adjuvant chemotherapy after radical resection of squamous cell carcinoma in the thoracic esophagus: who benefits? A retrospective study. Dig Surg. 2003;20(3):229–35; discussion 36-7.CrossRefPubMed
22.
Hiyoshi Y, Yoshida N, Watanabe M, Kurashige J, Karashima R, Iwagami S, et al. Late recurrence after radical resection of esophageal Cancer. World J Surg. 2016;40(4):913–20.CrossRefPubMed
23.
Wu SG, Dai MM, He ZY, Sun JY, Lin HX, Lin H, et al. Patterns of regional lymph node recurrence after radical surgery for thoracic esophageal squamous cell carcinoma. Ann Thorac Surg. 2016;101(2):551–7.CrossRefPubMed
24.
Guo JC, Lin CC, Huang TC, Huang PM, Kuo HY, Chang CH, et al. Number of resected lymph nodes and survival of patients with locally advanced esophageal squamous cell carcinoma receiving preoperative Chemoradiotherapy. Anticancer Res. 2018;38(3):1569–77.PubMed
25.
Lin CS, Cheng CT, Liu CY, Lee MY, Hsiao MC, Shih CH, et al. Radical lymph node dissection in primary Esophagectomy for esophageal squamous cell carcinoma. Ann Thorac Surg. 2015;100(1):278–86.CrossRefPubMed
26.
Taniyama Y, Nakamura T, Mitamura A, Teshima J, Katsura K, Abe S, et al. A strategy for supraclavicular lymph node dissection using recurrent laryngeal nerve lymph node status in thoracic esophageal squamous cell carcinoma. Ann Thorac Surg. 2013;95(6):1930–7.CrossRefPubMed
27.
Wang Q. The left thoracotomy approach for oncologic esophageal resection is still relevant for the modern surgical trainee Reply Ann Thorac Surg 2015;100(4):1516–1516.
28.
Tan ZH, Ma GW, Zhao JM, Bella AE, Rong TH, Fu JH, et al. Impact of thoracic recurrent laryngeal node dissection: 508 patients with tri-incisional Esophagectomy. J Gastrointest Surg. 2014;18(1):187–93.CrossRefPubMed
29.
Worrell SG, Alicuben ET, Oh DS, Hagen JA, DeMeester SR. Accuracy of clinical staging and outcome with primary resection for local-regionally limited esophageal adenocarcinoma. Ann Surg. 2018;267(3):484–8.CrossRefPubMed
30.
Miao LS, Chen HQ, Xiang JQ, Zhang YW. A high body mass index in esophageal cancer patients is not associated with adverse outcomes following esophagectomy. J Cancer Res Clin Oncol. 2015;141(5):941–50.CrossRefPubMed
31.
Cummings LC, Kou TD, Schluchter MD, Chak A, Cooper GS. Outcomes after endoscopic versus surgical therapy for early esophageal cancers in an older population. Gastrointest Endosc. 2016;84(2):232–40e1.CrossRefPubMedPubMedCentral
32.
Yamashita K, Makino T, Miyata H, Miyazaki Y, Takahashi T, Kurokawa Y, et al. Postoperative infectious complications are associated with adverse oncologic outcomes in esophageal Cancer patients undergoing preoperative chemotherapy. Ann Surg Oncol. 2016;23(6):2106–14.CrossRefPubMed
33.
Maas KW, Cuesta MA, van Berge Henegouwen MI, Roig J, Bonavina L, Rosman C, et al. Quality of life and late complications after minimally invasive compared to open Esophagectomy: results of a randomized trial. World J Surg. 2015;39(8):1986–93.CrossRefPubMedPubMedCentral
34.
Murakami Y, Hamai Y, Emi M, Hihara J, Imano N, Takeuchi Y, et al. Long-term results of neoadjuvant chemoradiotherapy using cisplatin and 5-fluorouracil followed by esophagectomy for resectable, locally advanced esophageal squamous cell carcinoma. J Radiat Res. 2018;59:616–24.CrossRefPubMedPubMedCentral
35.
Hamai Y, Hihara J, Emi M, Furukawa T, Murakami Y, Nishibuchi I, et al. Evaluation of prognostic factors for esophageal squamous cell carcinoma treated with neoadjuvant Chemoradiotherapy followed by surgery. World J Surg. 2018;42(5):1496–505.CrossRefPubMed
Metadata
Title
RETRACTED ARTICLE: Comparison of minimally invasive Ivor Lewis esophagectomy and left transthoracic esophagectomy in esophageal squamous cell carcinoma patients: a propensity score-matched analysis
Authors
Qi Wang
Zixiang Wu
Tianwei Zhan
Shuai Fang
Sai Zhang
Gang Shen
Ming Wu
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-5656-7

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue

Research article

Cost burden associated with advanced non-small cell lung cancer in Europe and influence of disease stage

Research article

Discordance in HER2 status between primary gastric adenocarcinoma tumors and cells from the corresponding malignant effusions

Study protocol

Second and third look laparoscopy in pT4 colon cancer patients for early detection of peritoneal metastases; the COLOPEC 2 randomized multicentre trial

Research article

Comparison of weekly and triweekly cisplatin regimens during concurrent chemoradiotherapy for nasopharyngeal carcinoma

Research article

Diagnostic accuracy of 13N-ammonia PET, 11C-methionine PET and 18F-fluorodeoxyglucose PET: a comparative study in patients with suspected cerebral glioma

Research article

Dynamic prediction of long-term survival in patients with primary gastric diffuse large B-cell lymphoma: a SEER population-based study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits